NCT06941844Phase 3Active not recruiting

A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)

Study sponsor: Definium Therapeutics US, Inc.

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-05-20Actual

Enrollment · participants149Actual

Source updated2026-08-28Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-06-22 · 2 fields changed

Completion date type changed

− Before

~~Estimated~~

+ After

Actual

Primary completion date changed

− Before

~~Nov 2026~~

+ After

20 May 2026

Check registry source

Posted 2026-03-02 · 3 fields changed

Participant count type changed

− Before

~~Estimated~~

+ After

Actual

Enrollment · participant count changed

− Before

~~140 participants (planned)~~

+ After

149 participants (actual)

Recruitment status changed

− Before

~~Recruiting~~

+ After

Active not recruiting

Check registry source

Study details

Conditions studied

Major Depressive Disorder

Treatments or interventions studied

DT120DrugAlso known as MM120, lysergide tartrate, LSD D-Tartrate

Primary outcomes · main study measures

Read the study measures

measure: Change from Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6; description: The MADRS is used to assess depression severity and to detect changes due to antidepressant treatment. The MADRS includes 10 clinician-completed items. Each of the 10 questions is scored with a range of 0-6 points. An item score of 0 indicates item not present or normal, while an item score of 6 indicates severe or continuous presence of the symptoms. The total possible score is 60, and higher scores represent a more severe condition.; timeFrame: Baseline to Week 6

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history